Endothelin: Emerging role in diabetic vascular complications

Diabetologia

Volumn 42, Issue 12, 1999, Pages 1383-1394

  Hopfner, R L ^a   Gopalakrishnan, V ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cardiova scular complications; Diabetes mellitus; Endothelial derived relaxing factor; Endothelin; Endothelium; Hyperglycaemia; Hyperlipidaemia; Insulin

Indexed keywords

ENDOTHELIN 1;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; DIABETIC ANGIOPATHY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MITOGENICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

DIABETIC ANGIOPATHIES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS;

EID: 0033406221     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051308     Document Type: Review

References (114)

1. 1. Yanagisawa M, Kurihara H, Kimura S et al. (1998) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415
2. 2. Haynes WG, Webb DJ (1998) Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098
3. 3. Vane JR, Angaard EA, Botting RM (1990) Regulatory functions of the vascular endothelium. N Eng J Med 323: 27-36
4. 4. Frelin C, Guedin D (1994) Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res 28: 1613-1622
5. 5. Wagner OF, Christ G, Woita J et al. (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068
6. 6. Lerman A, Edward BS, Hallet JW, Heublein DM, Sandberg SM, Burnett JC (1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Eng J Med 325: 997-1001
7. 7. Takeda Y, Miyamori I, Yoneda T, Takeda R (1991) Production of endothelin-1 from the mesenteric arteries of streptozotocin induced diabetic rats. Life Sci 48: 2553-2556
8. 8. Baumgartner-Parzer SM, Nowotny P, Wagner O, Waldhäusl W (1998) Determination of plasma ET-1 by RIA-risks and limitations. Horm Metab Res 30: 633-635
9. 9. Tada H, Muramatsu I, Nakai T, Kigoshi S, Miyabo S (1994) Effects of chronic diabetes on the responsiveness to endothelin-1 and other agents of rat atria and thoracic aorta. Gen Pharmacol 25: 1221-1228
10. 10. Makino A, Kamata K (1998) Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 123: 1065-1072
11. 11. Hopfner RL, McNeill JR, Gopalakrishnan V (1999) Endothelin plasma levels and endothelin-1 evoked vascular responses at different temporal stages of diabetes in streptozotocin diabetic rats. Eur J Pharmacol 374: 221-227
12. 12. Takahashi K, Suda K, Lam HC, Ghatei MA, Bloom SR (1991) Endothelin like immunoreactivity in rat models of diabetes mellitus. J Endocrinol 130: 123-127
13. 13. Frank HJ, Levin ER, Hu RM, Pedram A (1993) Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology 133: 1092-1097
14. 14. Hopfner RL, Misurski D, Wilson TW, McNeill JR, Gopalakrishnan V (1998) Insulin and vanadate restore decreased plasma endothelin concentrations and exaggerated vascular responses to normal in the streptozotocin diabetic rat. Diabetologia 41: 1233-1240
15. 15. Takahashi K, Ghatei MA, Lam HC, O'Hallaran DJ, Bloom SR (1990) Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33: 306-310
16. 16. Collier A, Leach JP, McClellan A, Jardine A, Morton JJ, Small M (1992) Plasma endothelin like immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 15: 1038-1040
17. 17. Haak T, Jungmann E, Felber A, Hillmann U, Usadel KH (1992) Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 5: 161-166
18. 18. Smulders RA, Stehouwer CD, Olthof CG et al. (1994) Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin-dependent diabetes mellitus. Clin Sci (Colch) 87: 37-43
19. 19. Malamitsi-Puchner A, Economou E, Katsouyanni K, Karachaliou F, Delis D, Bartsocas CS (1996) Endothelin 1-21 plasma concentrations in children and adolescents with insulin dependent diabetes mellitus. J Paediatr Endocrinol Metab 9: 463-468
20. 20. Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S (1994) Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 25: 159-164
21. 21. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R (1995) Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 18: 87-89
22. 22. Kanno K, Hirata Y, Shichiri M, Marumo F (1991) Plasma endothelin-1 levels in patients with diabetes mellitus with or withour vascular complication. J Cardiovasc Pharmacol 17[Suppl 7]:S475-S476
23. 23. Guvener N, Aytemir K, Aksoyek S, Gedik O (1997) Plasma endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coron Artery Dis 8: 253-258
24. 1, but not noradrenaline of aorta of from rats with streptozotocin induced diabetes mellitus. Br J Pharmacol 104: 928-932
25. 25. Guillon JM, Thiry C, Roach AG, Cavero I (1998) Preferential reduction in vascular responses to endothelin-1 in rats with streptozotocin induced diabetes. J Cardiovasc Pharmacol 31[Suppl 1] :S133-S137
26. 26. Awazu M, Parker RE, Harvie BR, Ichikawa I, Kon V (1991) Down regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats. J Cardiovasc Pharmacol 17[Suppl 7]:S500-S502
27. 27. Clozel M, Loffler BM, Breu V, Hilfiger L, Maire JP, Butscha B (1993) Downregulation of endothelin receptors by autocrine production of endothelin-1. Am J Physiol 265:C188-C192
28. 28. White RE, Carrier GO (1990) Vascular contraction induced by activation of membrane calcium ion channels in streptozotocin diabetes. J Pharmacol Exp Ther 253: 1057-1062
29. 29. Abebe W, Macleod KM (1990) Protein kinase C mediated contractile responses of arteries from diabetic rats. Br J Pharmacol 101: 465-471
30. A receptor expression in aortic smooth muscle cells. Diabetes 47: 937-944
31. 31. Zemel B, Sowers JR, Shehin S, Walsh F, Levy J (1990) Impaired calcium metabolism assoiated with hypertension in zucker obese rats. Metabolism 39: 704-708
32. 32. Hopfner RL, McNeill JR, Gopalakrishnan V (1998) Vanadate treatment normalizes exaggerated vascular responses in the obese Zucker rat. Eur J Pharmacol 357: 61-65
33. 33. Christensen KL, Mulvany MJ (1993) Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats. J Vasc Res 30: 73-79
34. 34. Hopfner RL, Misurski DA, McNeill JR, Gopalakrishnan V (1999) Effect of sodium orthovanadate treatment on cardiovascular function in the hyperinsulinaemic, insulin resistant obese Zucker rat. J Cardiovasc Pharmacol "in press"
35. 35. Misurski DA, Hopfner RL, McNeill JR, Gopalakrishnan V (1999) Perfused mesenteric vascular bed responses in the streptozotocin diabetic rat are dependent on the stage of diabetes: a focus on the vascular endothelium. Proc West Pharmacol Soc 42: 49-51
36. 36. Gardiner SM, Compton AM, Bennett T (1989) Regional haemodynamic effects of endothelin-1 in conscious, unrestrained, Wistar rats. J Cardiovasc Pharmacol 13[Suppl 5]:S202-S204
37. 37. Haynes WG, Gerro CJ, O'Kane KP, Somerville D, Omax CC, Webb DJ (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93: 1860-1870
38. 38. Kiff RJ, Gardiner SM, Compton AM, Bennett T (1991) The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 103: 1321-1326
39. 39. Sorenson SS, Madsen JK, Pedersen EB (1994) Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 266:F411-F418
40. 40. Lawrence E, Brain SD (1992) Altered microvascular reactivity to endothelin-1, endothelin-1, and NG-nitro-L-arginine methyl ester in streptozotocin induced diabetes mellitus. Br J Pharmacol 106: 1035-1040
41. 41. Nugent AG, McGurk C, Hayes JR, Johnston GD (1996) Impaired vasoconstriction to endothelin-1 in patients with NIDDM. Diabetes 45: 105-107
42. 42. Parving HH, Viberti GC, Keen H, Christiansen JS, Lassen NA (1983) Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 32: 943-949
43. 43. Hsueh WA, Anderson PW (1992) Hypertension, the endothelial cell. And the vascular complications of diabetes mellitus. Hypertension 20: 253-263
44. 44. Vierhapper H, Wagner O, Nowotny P, Waldhäusl W (1990) Effect of endothelin-1 in man. Circulation 81: 1415-1418
45. 45. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338: 784-790
46. 46. Epstein M, Sowers JR (1992) Diabetes mellitus and hypertension. Hypertension 19: 403-418
47. 47. Fernandez AC, Patino R, Ibarra J et al. (1995) Endothelin in hypertension and diabetes mellitus. In: Luscher TF (ed) Endothelin in cardiovascular diseases. Springer, Berlin Heidelberg, New York, pp 157-170
48. 48. Perfetto F, Tarquini R, de Leonardis V et al. (1997) Vascular damage and not hypertension per se influences endothelin-1 plasma levels in patients with non insulin dependent diabetes mellitus. Recenti Prog Med 88: 317-320
49. 49. Winkles JA, Alberts GF, Brogi E, Libby P (1993) Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 191: 1081-1088
50. B receptor antagonist bosentan inhibits neo-intimal development in collared carotid arteries of rabbits. Life Sci 63:PL259-PL266
51. 51. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF (1998) Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apoliprotein E-deficient mice. Proc Natl Acad Sci USA 95: 14367-14372
52. 52. Perfetto F, Tarquini R, Tapparini L, Tarquini B (1998) Influence of non-insulin dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 12: 187-192
53. 53. Young MJ, Veves A, Walker MG, Boulton AJM (1992) Correlations between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy? Diabetologia 35: 1146-1150
54. 54. Zochodne DW, Cheng C, Sun H (1998) Diabetes increases sciatic nerve susceptibility to endothelin induced ischaemia. Diabetes 45: 627-632
55. 55. Cameron NE, Dines KC, Cotter MA (1994) The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin diabetic rats. Diabetologia 37: 1209-1215
56. 56. Stevens EJ, Tomlinson DR (1995) Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br J Pharmacol 115: 373-379
57. 57. Cameron NE, Cotter MA (1996) Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system. J Pharmacol Exp Ther 278: 1262-1268
58. 58. Kohner EM, Patel V, Rassam SM (1995) Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 44: 603-607
59. 59. Pang I-H, Yorio T (1997) Ocular actions of endothelins. Proc Soc Exp Biol Med 215: 21-34
60. 60. De la Rubia G, Oliver FJ, Inoguchi T, King GL (1992) Induction of resistance to endothelin-1's biochemical actions by elevated glucose levels in retinal pericytes. Diabetes 41: 1533-1539
61. 61. Chakravarthy U, McGinty A, McKillop J, Anderson P, Archer DB, Trimble ER (1994) Altered endothelin-1 induced contraction and second messenger generation in bovine retinal microvascular pericytes cultured in high glucose medium. Diabetologia 37: 36-42
62. 62. Bursell SE, Clermont AC, Oren B, King GL (1995) The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats. Invest Ophthalmol Vis Sci 36: 596-607
63. 63. Takagi C, Bursell SE, Lin YW et al. (1996) Regulation of retinal haemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 37: 2504-2518
64. 64. Ogata M, Naruse M, Iwasaki N et al. (1998) Immunoreactive endothelin levels in the vitreous fluid are decreased in diabetic patients with proliferative retinopathy. J Cardiovasc Pharmacol 31[Suppl 1]:S378-S379
65. 65. Kawamura M, Ohgawara H, Naruse M et al. (1992) Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 15: 1396-1397
66. 66. Laurenti O, Vingolo EM, Desideri GB et al. (1997) Increased levels of plasma endothelin-1 in on-insulin dependent diabetic patients with retinopathy but without other diabetes related organ damage. Exp Clin Endocrinol Diabetes 105[Suppl 2]:40-42
67. 67. Kohan DE (1991) Endothelins in the normal and diseased kidney. Am J Kidney Dis 29: 2-26
68. 68. Morabito E, Corsico N, Serafini S, Martelli EA (1994) Elevated urinary excretion of endothelins in streptozotocin diabetic rats. Life Sci 54:PL197-PL200
69. 69. Turner NC, Morgan PJ, Haynes AC et al. (1997) Elevated renal endothelin-1 clearance and mRNA levels associated with albuminuria and nephropathy in non-insulin dependent diabetes mellitus: studies in obese fa/fa Zucker rats. Clin Sci (Colch) 93: 565-571
70. 70. Shin SJ, Lee YJ, Lin SR, Tan MS, Lai YH, Tsai JH (1995) Decrease of renal endothelin-1 content and gene expression in diabetic rats with moderate hyperglycaemia. Nephron 70: 486-493
71. 71. Vesci L, Mattera GG, Tobia P, Corsico N, Calvani M (1995) Cardiac and renal endothelin-1 binding sites in streptozotocin induced diabetic rats. Pharmacol Res 32: 363-367
72. 72. Fukui M, Nakamura T, Ebihara I et al. (1993) Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 122: 149-156
73. 73. Nakamura I, Saito M, Fukumoto Y et al. (1997) Experimental diabetes upregulates the expression of ureteral endothelin receptors. Peptides 18: 1091-1093
74. 74. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H (1995) Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44 :895-899
75. 75. Hocher B, Lun A, Priem F, Neumayer HH, Raschack M (1998) Renal endothelin system in diabetes: comparison of angiotensin converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol 31[Suppl 1]:S492-S495
76. 76. Benigni A, Colosio V, Brena C et al. (1998) Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47: 450-456
77. 77. Lee YJ, Shin SJ, Tsai JH (1994) Increased urinary endothelin-1 like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care 17: 263-266
78. 78. De Mattia G, Cassone-Faldetta M, Bellini C et al. (1998) Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens 11: 983-988
79. 79. Blauw GJ, Westendorp RG, Srivistava N et al. (1995) Hypoxia induced arterial endothelin does not influence peripheral vascular tone. J Cardiovasc Pharmacol 26[Suppl 3]:S242-S243
80. 80. Liu J, Chen R, Casley DJ, Nayler WN (1990) Ischemia and reperfusion increase 1251-labeled endothelin-1 binding in rat cardiac membranes. Am J Physiol 258:H829-H835
81. 81. Douglas SA, James S, Hiley CR (1991) Endothelial modulation and changes in endothelin pressor activity during hypoxia in the rat isolated perfused mesenteric arterial bed. Br J Pharmacol 103: 1441-1448
82. 82. Omland T, Lie RT, Aakvaag A, Arsland T, Dickstein K (1994) Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89: 1573-1579
83. 83. Benigni A, Remuzzi G (1999) Endothelin antagonists. Lancet 353: 133-138
84. 84. Williamson JR, Chang K, Frangos M et al. (1992) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813
85. 85. Tahiliani AG, McNeill JH (1986) Diabetes induced abnormalities in the myocardium. Life Sci 38: 959-974
86. 86. Mankovsky BN, Metzger BE, Molitch ME, Biller J (1996) Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complications 10: 228-242
87. 87. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H (1990) Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 267: 16-18
88. 88. Hattori Y, Kasai K, Nakamura T, Emoto T, Shimoda S-I (1991) Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism 40: 165-169
89. 89. Metsarrine K, Saijonmaa O, Yki-Jarvinen H, Fyhrquist F (1994) Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism 43: 878-882
90. 90. Baumgartner-Parzer S, Wagner O, Waldhäusl W, Roth T, Lorenzi M (1996) Failure of high ambient glucose to affect endothelin-1 synthesis or release by cultured human endothelial cells. Horm Metab Res 28: 610-612
91. 91. Sandirasegarane L, Herman RJ, Gopalakrishnan V (1994) High glucose attenuates peptide agonist-evoked increases in cytosolic free [Ca2 +] in rat aortic smooth muscle cells. Diabetes 43: 1033-1040
92. 92. Oliver FJ, de la Rubia G, Feener EP et al. (1991) Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 266: 23251-23256
93. 93. Ferri C, Pittoni V, Piccoli A et al. (1995) Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 80: 829-835
94. 94. Anfossi G, Cavalot F, Massucco P et al. (1993) Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells. Metabolism 42: 1081-1083
95. 95. Piatti PM, Monti LD, Conti M et al. (1996) Hypertriglyceridemia and hyperinsulinaemia are potent inducers of endothelin-1 release in humans. Diabetes 45: 316-321
96. 96. Juan CC, Fang VS, Hsu YP et al. (1998) Overexpression of vascular endothelin-1 and endothelin-A receptors in fructose induced hypertensive rat model. J Hypertens 16: 1775-1782
97. 2+ store in porcine coronary artery smooth muscle. Diabetes 45: 876-880
98. 98. Hasdai D, Holmes DR Jr, Richardson DM, Izhar U, Lerman A (1998) Insulin and IGF-1 attenuate the coronary vasoconstrictor effects of endothelin-1 but not sarafotoxin 6c. Cardiovasc Res 39: 644-650
99. 99. Nava P, Collados MT, Masso F, Guarner V (1997) Endothelin mediation of insulin and glucose induced changes in vascular contractility. Hypertension 30: 825-829
100. 100. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P (1992) Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 117: 42-47
101. 101. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF (1992) Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 70: 1191-1197
102. 102. Horio T, Kohno M, Yasunari K et al. (1993) Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells. Atherosclerosis 101: 185-190
103. 103. Uyama H, Haraoka S, Shimokama T, Goto K, Dohi K, Watanabe T (1996) Diet induced hypercholesterolemia increases endothelin-1 release by aortic endothelial cells. Pathobiology 64: 328-332
104. 104. Lerman A, Webster MW, Chesebro JH et al. (1993) Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 88: 2923-2928
105. 105. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Polizzi G, Tamburino G (1996) Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Int Angiol 15: 240-244
106. 106. Merkel LA, Bilder GE (1992) Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits. Eur J Pharmacol 222: 175-179
107. 107. Mathew V, Cannan CR, Miller V et al. (1997) Enhanced endothelin mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 96: 1930-1936
108. 108. Wascher TC, Toplak H, Krejs GJ, Simecek S, Kukovetz WR, Graier WF (1994) Intracellular mechanisms involved in D-glucose mediated amplification of agonist-induced Ca2 + response and EDRF formation in vascular endothelial cells. Diabetes 43: 984-991
109. 109. Pieper G (1998) Review of alterations in endothelial nitric oxide production in diabetes. Hypertension 31: 1047-1060
110. 110. Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87: 432-438
111. 111. Chang KC, Chung SY, Chong WS et al. (1993) Possible superoxide radical induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther 266: 992-1000
112. 112. Pieper GM (1999) Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 42: 204-213
113. 113. Boulanger C, Luscher TF (1990) Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590
114. 114. Vermes I, Spooren PF, Kalsbeek-Batenburg EM, Haanen C (1993) In addition to von Willebrand factor and urinary albumin excretion, plasma endothelin is an indicator of endothelial dysfunction in diabetes mellitus. Diabetologia 36: 472-473